Clinical Trial of Comparative Study of GB221 Pharmacokinetics
Status:
Completed
Trial end date:
2012-03-08
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the safety of a single dose of GB221 compared to
Herceptin® when administered as a single IV injection at a dose of 8 mg/kg. The secondary
objective of the study is to assess the pharmacokinetics of GB221 compared to Herceptin®.